Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antony Loebel

Showing results (21-30 of 128) with videos related to

Pageof 13
Sort By:
Journal of Medical Economics|May 19, 2015
Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depressionKrithika Rajagopalan, Kellie Meyer, Ken O'Day, et al.
International Clinical Psychopharmacology|October 6, 2007
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week studyDan Zimbroff, Lewis Warrington, Antony Loebel, et al.
Annals of the New York Academy of Sciences|January 16, 2016
The development of lurasidone for bipolar depressionAntony Loebel, Jane Xu, Jay Hsu, et al.
Innovations in Clinical Neuroscience|February 8, 2018
Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) FactorsSeth C Hopkins, Ajay Ogirala, Antony Loebel, et al.
Psychopharmacology|June 20, 2006
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvementsPhilip D Harvey, Michael F Green, Christopher Bowie, et al.
BMC Health Services Research|April 6, 2018
Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysisJohn W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, et al.
International Journal of Methods in Psychiatric Research|June 27, 2018
Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features)Steven D Targum, J Cara Pendergrass, Sang Lee, et al.
Journal of Comparative Effectiveness Research|April 27, 2018
Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysisDaisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, et al.
Human Psychopharmacology|September 10, 2013
Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studiesSheldon Preskorn, Larry Ereshefsky, Yu-Yuan Chiu, et al.
Clinical Therapeutics|January 6, 2016
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response AnalysisSunny Chapel, Yu-Yuan Chiu, Jay Hsu, et al.
Pageof 13

Showing results (21-30 of 128) with videos related to

Sort By:
Pageof 13
Journal of Medical Economics|May 19, 2015
Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depressionKrithika Rajagopalan, Kellie Meyer, Ken O'Day, et al.
International Clinical Psychopharmacology|October 6, 2007
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week studyDan Zimbroff, Lewis Warrington, Antony Loebel, et al.
Annals of the New York Academy of Sciences|January 16, 2016
The development of lurasidone for bipolar depressionAntony Loebel, Jane Xu, Jay Hsu, et al.
Innovations in Clinical Neuroscience|February 8, 2018
Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) FactorsSeth C Hopkins, Ajay Ogirala, Antony Loebel, et al.
Psychopharmacology|June 20, 2006
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvementsPhilip D Harvey, Michael F Green, Christopher Bowie, et al.
BMC Health Services Research|April 6, 2018
Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysisJohn W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, et al.
International Journal of Methods in Psychiatric Research|June 27, 2018
Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features)Steven D Targum, J Cara Pendergrass, Sang Lee, et al.
Journal of Comparative Effectiveness Research|April 27, 2018
Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysisDaisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, et al.
Human Psychopharmacology|September 10, 2013
Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studiesSheldon Preskorn, Larry Ereshefsky, Yu-Yuan Chiu, et al.
Clinical Therapeutics|January 6, 2016
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response AnalysisSunny Chapel, Yu-Yuan Chiu, Jay Hsu, et al.
Pageof 13